Literature DB >> 3338084

Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line.

R A Nakashima1, M G Paggi, L J Scott, P L Pedersen.   

Abstract

Recent studies from this laboratory have demonstrated that a form of hexokinase characteristic of rapidly growing, highly glycolytic tumor cells is bound to an outer mitochondrial membrane receptor complex containing a Mr 35,000 pore protein (D. M. Parry and P. L. Pedersen, J. Biol. Chem., 258: 10904-10912, 1983; R. A. Nakashima, et al., Biochemistry, 25: 1015-1021, 1986). In new studies reported here the specificity of this receptor complex for binding hexokinase is defined, and a purification scheme is described which leads to a homogeneous and bindable form of the tumor hexokinase. In the AS-30D hepatoma, hexokinase activity is elevated more than 100-fold relative to liver tissue. The relative increase in hexokinase activity is 8 times greater than that of any other glycolytic enzyme. Hexokinase is the only glycolytic enzyme of AS-30D cells to exhibit a mitochondrial/cytoplasmic specific activity ratio greater than 1, showing a 3.5-fold elevation in the mitochondrial fraction. Purification of hexokinase is accomplished by preferential solubilization of the mitochondrial bound enzyme with glucose-6-phosphate, followed by high-performance liquid chromatography on gel permeation and anion exchange columns. The final fraction has a specific activity of 144 units per mg of protein, with a Km for glucose of 0.13 mM and for ATP of 1.4 mM. The purified tumor enzyme migrates as a single species upon sodium dodecyl sulfate: polyacrylamide gel electrophoresis with an apparent molecular weight of 98,000. Significantly, the purified tumor enzyme retains its activity for mitochondrial binding. Additional results derived from chromatographic, polyclonal antibody, and amino acid analysis studies indicate that the predominant rat hepatoma hexokinase species is related most closely to isozymic form(s) of the enzyme commonly referred to as type II, and least related to the liver type IV isozyme (glucokinase).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338084

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Model of the outer membrane potential generation by the inner membrane of mitochondria.

Authors:  Victor V Lemeshko
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

2.  Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.

Authors:  Lei Gong; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Jirun Peng; Xisheng Leng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

3.  Comparative analysis of some aspects of mitochondrial metabolism in differentiated and undifferentiated neuroblastoma cells.

Authors:  Aleksandr Klepinin; Vladimir Chekulayev; Natalja Timohhina; Igor Shevchuk; Kersti Tepp; Andrus Kaldma; Andre Koit; Valdur Saks; Tuuli Kaambre
Journal:  J Bioenerg Biomembr       Date:  2013-09-27       Impact factor: 2.945

4.  Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells.

Authors:  Lei Gong; Zhuqingqing Cui; Xin Yu; Yuhua Wei; Jirun Peng; Xisheng Leng
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

Review 5.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Biochim Biophys Acta       Date:  2010-04-08

6.  Hexokinase 'binding sites' of normal and tumoral human brain mitochondria.

Authors:  A Golestani; M Nemat-Gorgani
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

7.  Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A.

Authors:  A Rempel; P Bannasch; D Mayer
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

Review 8.  VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation.

Authors:  Diana Fang; Eduardo N Maldonado
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 9.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

Review 10.  Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.